研究目的
Investigating site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals to improve the sensitivity and specificity of molecular imaging in the development of antibody-based therapies.
研究成果
Site-specifically radiolabelled antibody-based radiopharmaceuticals will deliver new clinically-useful contrast agents for molecular PET/SPECT imaging, providing clinicians with better molecular imaging tools to predict patient response to treatment and scientists with reliable tools to quantitatively map the in vivo behaviour of new antibody-based therapies and newly-discovered receptors that are drug targets.
研究不足
The study reviews existing methods and does not present new experimental data, thus the limitations are related to the current state of technology in site-specific conjugation methods and their application in clinical settings.
1：Experimental Design and Method Selection:
The study reviews existing site-specific chelator-protein conjugation methods, including chelator attachment to cysteines/disulfide bonds or the glycan region of the antibody, enzyme-mediated chelator conjugation, and incorporation of sequences of amino acids that chelate the radiometal.
2：Sample Selection and Data Sources:
The study surveys existing literature and methodologies for site-specific conjugation of chelators to antibodies for PET and SPECT imaging.
3：List of Experimental Equipment and Materials:
Not explicitly mentioned in the provided text.
4：Experimental Procedures and Operational Workflow:
The study describes the conjugation strategies and their applications in radiolabelling antibodies for imaging.
5：Data Analysis Methods:
The study evaluates the effectiveness of different conjugation methods based on their ability to produce well-defined constructs with superior properties for imaging.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
